Telehealth startup Done’s top leadership arrested on fraud charges

The CEO and clinical president of a closely watched telehealth startup prescribing the ADHD medication Adderall online have been arrested and charged with fraud, the Justice Department announced Thursday.

Done founder Ruthia He and clinical president David Brody were arrested in Los Angeles and San Rafael, Calif., respectively. They were charged with allegedly taking part in a scheme to distribute controlled substances online and submitting false and fraudulent reimbursement claims for stimulant prescriptions.

The company, known for ubiquitous social media ads boasting treatment for ADHD, charges $79-a-month memberships following an initial $119 charge for fast assessments and online appointments with “worry-free” refills.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

AbbVie asks Supreme Court to reconsider ruling on attorney-client communication

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 12, 2024

Inflammatory diseases don’t boost clotting risks post-COVID, study reveals

Canadian researchers found that patients with immune-mediated inflammatory diseases (IMIDs) don’t face a heightened risk of venous thromboembolism events after recovering from COVID-19 compared to

October 11, 2023

Madrigal to grapple with lack of awareness about NASH ahead of potential FDA approval

Madrigal Pharmaceuticals may be first in line to bring a NASH drug to market, but the company is also tasked with teaching Americans and their

March 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.